Physician profile
Michael A Werner
NPI 1124340294
$10,705.25
in general payments reported to CMS, 2019-2025
28 companies · $675 in 2025
The $675 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $718 · 2020: $840 · 2021: $1,555 · 2022: $5,607 · 2023: $757 · 2024: $553 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,958 · Debt Forgiveness: $27.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,958.19 |
| Debt Forgiveness | $27.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acerus Pharmaceuticals Corporation | $4,589.78 | 2021-2022 | |
| Abbvie INC. | $1,177.86 | 2021-2024 | Vraylar |
| Bausch Health US, LLC | $907.58 | 2019-2024 | Wellbutrin, Aplenzin |
| Endo Pharmaceuticals INC. | $751.96 | 2019-2024 | Edex, Xiaflex, Aveed |
| Takeda Pharmaceuticals U.S.A., INC. | $627.27 | 2019-2023 | Trintellix |
| Viiv Healthcare Company | $539.82 | 2022-2025 | Apretude |
| Gilead Sciences, INC. | $438.95 | 2019-2024 | |
| Antares Pharma, INC. | $437.87 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Endo USA, INC. | $313.56 | 2024-2025 | Xiaflex, Aveed |
| Allergan, INC. | $260.95 | 2019-2020 | |
| Stryker Corporation | $91.10 | 2025 | N/A |
| Tolmar, INC. | $87.48 | 2023-2025 | Jatenzo |
| Clarus Therapeutics INC. | $64.35 | 2021 | |
| Boston Scientific Corporation | $60.86 | 2021-2025 | Ams 700 |
| Lilly USA, LLC | $46.87 | 2025 | Zepbound, Mounjaro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $41.02 | 2023 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $29.25 | 2023 | Quviviq |
| Vitrolife INC. | $27.10 | 2024 | |
| Coloplast Corp | $26.99 | 2021 | |
| Ambu INC. | $26.18 | 2022 | |
| Merck Sharp & Dohme LLC | $24.29 | 2023 | Welireg |
| Evofem Biosciences, INC. | $22.63 | 2022 | |
| Owp Pharmaceuticals, INC. | $21.59 | 2023 | Subvenite, Lamotrigine |
| Novo Nordisk INC | $21.15 | 2024 | Wegovy, Saxenda |
| Kerr Corporation | $20.74 | 2020 | |
| Currax Pharmaceuticals LLC | $17.00 | 2025 | Contrave |
| Therapeuticsmd, INC. | $15.63 | 2022 | |
| Myriad Genetic Laboratories, INC. | $15.42 | 2023 | Myrisk |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Werner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.